Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Join this interactive Webinar where faculty will provide their perspective on how to co-manage T2D and HF with case-based examples, patient management, and recommendations on how these disciplines can come together to collaborate on prevention of HF progression in diabetic patients.


7:00 PM ET     Opening Remarks, Preactivity Polling
7:05 PM ET     Heart Failure in Diabetes—Overview of the Problem
7:15 PM ET     SGLT2 Inhibition in Patients With Diabetes
7:30 PM ET     Leveraging SGLT2 Inhibitors in T2D and HF: A Shared Approach
7:45 PM ET     Postactivity Polling, Question and Answer Session With Case Discussion
8:00 PM ET     Adjournment


Date / Time
Event Details


Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Mikhail Kosiborod, MD

Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist
Division of Cardiovascular Research
Department of Cardiology
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

Goal Statement
The goals of this program are to improve endocrinologists’ and other clinicians’ understanding and competence in leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in patients with type 2 diabetes.

Target Audience
This activity is intended for endocrinologists, cardiologists, internists, primary care physicians, advanced practice providers,  and other healthcare providers who care for individuals with diabetes who are at risk for worsening HF.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify the pathologic mechanisms by which diabetes can lead to the development of HF
  • Characterize HF outcomes from CVOTs of SGLT2 inhibitors in patients with T2D
  • Describe strategies to foster collaboration between endocrinologists and cardiologists to optimize care of patients with T2D and HF


The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit:

The Endocrine Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.